---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-25-000073"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:26:54.478804+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Humacyte posts Q1 net income $39.1M; Symvess launch generates $147K revenue

## Summary
- Q1 2025 revenue $517K ($147K from first Symvess commercial sales); no revenue in Q1 2024.
- Net income of $39.1M vs net loss of $31.9M YoY, driven by $62.3M non-cash remeasurement gain.
- Cash and equivalents $113.2M; $46.7M net from March public offering extended runway.
- Reduced workforce by ~31 employees; expects net savings of $13.8M in 2025, over $50M by 2026.
- 45 hospitals initiated Symvess VAC approval; 5 approved. On track for dialysis BLA in 2026.

## SEC filing metadata
- accession: 0001818382-25-000073
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838225000073/0001818382-25-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838225000073/huma-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-25-000073
- JSON: https://secwatch.observer/filing/0001818382-25-000073.json
- Plain text: https://secwatch.observer/filing/0001818382-25-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.